AZN•benzinga•
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
Summary
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 15, 2025 by benzinga